TW202325851A - 用於治療劑遞送之組合物及方法 - Google Patents

用於治療劑遞送之組合物及方法 Download PDF

Info

Publication number
TW202325851A
TW202325851A TW111140482A TW111140482A TW202325851A TW 202325851 A TW202325851 A TW 202325851A TW 111140482 A TW111140482 A TW 111140482A TW 111140482 A TW111140482 A TW 111140482A TW 202325851 A TW202325851 A TW 202325851A
Authority
TW
Taiwan
Prior art keywords
retroviral vector
interleukin
recombinant retroviral
polynucleotide sequence
individual
Prior art date
Application number
TW111140482A
Other languages
English (en)
Chinese (zh)
Inventor
布里列 鐘
瑟西利亞 羅
羅伯特 Ｇ 強森
Original Assignee
美商吉恩維沃公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商吉恩維沃公司 filed Critical 美商吉恩維沃公司
Publication of TW202325851A publication Critical patent/TW202325851A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW111140482A 2021-10-25 2022-10-25 用於治療劑遞送之組合物及方法 TW202325851A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163271674P 2021-10-25 2021-10-25
US63/271,674 2021-10-25
US202263413165P 2022-10-04 2022-10-04
US63/413,165 2022-10-04

Publications (1)

Publication Number Publication Date
TW202325851A true TW202325851A (zh) 2023-07-01

Family

ID=86158435

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111140482A TW202325851A (zh) 2021-10-25 2022-10-25 用於治療劑遞送之組合物及方法

Country Status (8)

Country Link
US (2) US12234475B2 (https=)
EP (1) EP4423287A4 (https=)
JP (1) JP2024540002A (https=)
KR (1) KR20240099339A (https=)
AU (1) AU2022375623A1 (https=)
CA (1) CA3235894A1 (https=)
TW (1) TW202325851A (https=)
WO (1) WO2023076177A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3235894A1 (en) 2021-10-25 2023-05-04 Brile Chung Compositions and methods for therapeutic delivery

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19651443A1 (de) 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
WO1998044938A1 (en) 1997-04-10 1998-10-15 University Of Southern California Modified proteins which bind extracellular matrix components
EP1914304A1 (en) 1998-10-14 2008-04-23 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
JP2002516061A (ja) * 1997-10-14 2002-06-04 ダーウィン モレキュラー コーポレイション チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質
US6743631B1 (en) 1998-03-17 2004-06-01 North Shore University Hospital Research Corporation Use of human serum resistant vector particles and cell lines for human gene therapy
GB9810999D0 (en) * 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
US6490476B1 (en) 1999-10-14 2002-12-03 Cti Pet Systems, Inc. Combined PET and X-ray CT tomograph and method for using same
US6825033B2 (en) 2000-03-02 2004-11-30 University Of Southern California Mutated cyclin G1 protein
US20010046491A1 (en) 2000-03-23 2001-11-29 Valerie Kristoffer C. Tumor radiosensitization with mutant thymidine kinase in combination with a prodrug
US20050130132A1 (en) 2002-09-06 2005-06-16 Day Craig H. Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20060216299A1 (en) 2002-10-30 2006-09-28 Rigel Pharmaceuticals, Inc. Cell cycle targets and peptides
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20090123428A1 (en) 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US7815902B2 (en) 2003-07-09 2010-10-19 Henry Ford Health System Methods and compositions for cancer therapy using a novel adenovirus
WO2005007109A2 (en) 2003-07-09 2005-01-27 Henry Ford Health System Methods and compositions for cancer therapy using a novel adenovirus
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
CA2643102A1 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California A method for noninvasively and quantitatively monitoring therapeutic and diagnostic transgene expression induced by ex vivo and in vivo gene targeting in organs, tissues and cells
PT2145189E (pt) 2007-05-08 2016-06-16 Us Health Pseudovírus de papilomavírus para deteção e terapêutica de tumores
CA2690627C (en) 2007-06-15 2014-12-02 Genelux Corporation Microorganisms for imaging and/or treatment of tumors
WO2009070636A2 (en) 2007-11-27 2009-06-04 Stanford University Engineered cells, imaging reporter gene/probe systems, and methods of imaging
US20090176260A1 (en) 2007-12-04 2009-07-09 Joseph Ching-Ming Wu Double-fusion human embryonic stem cells, methods of making double-fusion human embryonic stem cells, triple-fusion human embryonic stem cells, methods of making triple-fusion human embryonic stem cells, and methods of monitoring double-fusion human embryonic stem cells and triple-fusion human embryonic stem cells
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
EP2376518A4 (en) 2008-12-18 2013-12-04 Avaris Ab COMPLEX AND METHOD FOR AMPLIFYING NUCLEAR RELEASE
KR101032871B1 (ko) 2009-07-10 2011-05-06 주식회사 바이오드 비엠피-2와 에이치에스브이-티케이 자살유전자를 동시에 포함하고 발현 할 수 있도록 하는 벡터와 이 벡터가 도입된 자가조절형 줄기세포 치료제
KR20140027063A (ko) 2010-10-28 2014-03-06 버지니아 커먼웰스 유니버시티 치료와 병용하는 암 영상화: 치료진단
JP2015505326A (ja) 2012-01-18 2015-02-19 ニューメディシンズ，インコーポレーテッド 放射線防護及び放射線誘発性毒性緩和のためのｉｌ−１２
AU2014236208B2 (en) 2013-03-14 2018-07-19 Genvivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
JP2018526007A (ja) * 2015-09-04 2018-09-13 トカジェン インコーポレーテッド ２ａペプチドを含む組換えベクター
WO2017147269A1 (en) * 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3568474A1 (en) * 2017-01-10 2019-11-20 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
WO2018150345A1 (en) * 2017-02-16 2018-08-23 De Vita Bio Life Sciences An expression vector
EP3592368A1 (en) * 2017-03-08 2020-01-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
JP7216668B2 (ja) * 2017-05-26 2023-02-01 エピセントアールエックス，インコーポレイテッド 導入遺伝子を保持する組換えアデノウイルス
EP3983444A4 (en) * 2019-06-14 2023-10-25 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
US12071633B2 (en) * 2020-10-13 2024-08-27 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
CA3235894A1 (en) 2021-10-25 2023-05-04 Brile Chung Compositions and methods for therapeutic delivery

Also Published As

Publication number Publication date
WO2023076177A3 (en) 2023-08-24
WO2023076177A2 (en) 2023-05-04
JP2024540002A (ja) 2024-10-31
US20250115930A1 (en) 2025-04-10
KR20240099339A (ko) 2024-06-28
EP4423287A4 (en) 2025-10-22
CA3235894A1 (en) 2023-05-04
EP4423287A2 (en) 2024-09-04
AU2022375623A1 (en) 2024-05-02
US12234475B2 (en) 2025-02-25
US20230265457A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
JP7246343B2 (ja) 改善されたチミジンキナーゼ遺伝子
JP6723982B2 (ja) インターロイキン−２／インターロイキン−２受容体アルファ融合タンパク質および使用方法
US11103555B2 (en) Compositions and methods for reducing tumor cell growth at a site of solid tumor excision
US12350327B2 (en) Compositions and methods for therapeutic or vaccine delivery
JP2021528101A (ja) 液体医薬組成物中で非常に安定な治療的に活性なアルデスロイキンを調製する方法
CN118451096A (zh) 异二聚体fc细胞因子及其用途
JP2026053539A (ja) Ｉｃｄ ｓｔａｔシグナル伝達が改変されたｃｄ１２２
US20250115930A1 (en) Compositions and methods for therapeutic delivery
TW202233661A (zh) 多功能及多價介白素-TGF-β受體融合多肽
CN118556129A (zh) 用于治疗剂递送的组合物和方法
Lasek et al. Interleukin 12: Antitumor activity and immunotherapeutic potential in oncology
JP2024509084A (ja) 核酸ベクター及び使用方法
CN118451188A (zh) 用于治疗剂或疫苗递送的组合物及方法
AU717974B2 (en) Transduced human hematopoietic stem cells
WO2024226784A2 (en) Compositions and methods for therapeutic or vaccine delivery
WO2025101551A1 (en) Prostate-specific membrane antigen (psma)-binding peptides and method of use
WO2026077330A1 (zh) 一种增强肿瘤杀伤能力的工程化细胞及其应用